Efficacy of Combined Levonorgestrel-Releasing Intrauterine System with Gonadotropin-Releasing Hormone Analog for the Treatment of Adenomyosis
article
OA: gold
CC0
⤵ 40 in-corpus citations
Abstract
OBJECTIVES: To evaluate the clinical outcomes of gonadotropin-releasing hormone analog (GnRHa) combined with implantation of a levonorgestrel-releasing intrauterine system (LNG-IUS) in adenomyosis patients with significantly enlarged uteruses. SUBJECTS AND METHODS: Twenty-one adenomyosis patients whose uterine volumes were greater in size than at 12 weeks' gestation were recruited for the study. Subcutaneous injection of GnRHa was administrated at an interval of 28 days for a total of 3-4 cycles when uterine length was determined to be less than 10 cm by ultrasound measurement. At 3, 6 and 12 months after LNG-IUS implantation, follow-up was performed to document the clinical values such as uterine volume, degree of dysmenorrhea and menstrual flow. RESULTS: Twelve months after implantation, the menstrual flow was significantly lower than baseline values (53.8 ± 11.7 vs. 100, p = 0.03). The degree of dysmenorrhea (pain) was relieved 12 months after implantation (58.2 ± 11.5 vs. 93.7 ± 0.2, p = 0.005). Uterine volume was also below pre-GnRHa levels after implantation (276.6 ± 32.1 vs. 311.4 ± 32.3, p = 0.005). LNG-IUS was expelled in 3 patients, giving an expulsion rate of 14%. Side effects of GnRHa combined with LNG-IUS implantation were few. CONCLUSION: The findings indicate that combined GnRHa and LNG-IUS treatment was efficacious in patients with enlarged adenomyosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (7)
- Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems via openalex
- Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study via openalex
- Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system via openalex
- Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device via openalex
- W2040770590 via openalex
- W2071970773 via openalex
- W2012607678 via openalex
Cited by (40)
- Efficacy of levonorgestrel releasing intrauterine system in the treatment of symptomatic adenomyosis: comparison with dienogest 2025
- Prognostic factors of progesterone resistance in symptomatic adenomyosis: impact of lesion localization on treatment outcome of levonorgestrel intrauterine system 2025
- High-intensity focused ultrasound combined with hysteroscopic insertion of levonorgestrel-releasing intrauterine system for intrinsic adenomyosis: a retrospective observational study 2025
- Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study 2024
- Clinical application of a simplified hysteroscopic LNG-IUD non-suture fixation in the treatment of adenomyosis 2024
- Effectiveness of high-intensity focused ultrasound combined with gonadotropin-releasing hormone agonist or combined with levonorgestrel-releasing intrauterine system for adenomyosis: A systematic review and meta-analysis 2024
- Clinical Efficacy of Levonorgestrel Releasing Intrauterine System versus Dienogest for Women having Symptomatic Adenomyosis 2023
- Evaluation of Endpoints Used in Clinical Trials on Adenomyosis - A Systematic Review 2023
- Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review 2022
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
- Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study 2022
- Clinical evaluation of high-intensity focused ultrasound ablation combined with mifepristone and levonorgestrel-releasing intrauterine system to treat symptomatic adenomyosis 2022
- An innovative surgical approach: suture fixation of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis 2022
- Medical Treatment of Adenomyosis 2022
- Characterization of patients that can continue conservative treatment for adenomyosis 2021
- Laparoscopically assisted Adenomyomectomy Using the Double/Multiple-Flap Method with Temporary Occlusion of the Bilateral Uterine Artery and Utero-Ovarian Vessels in Comparison with the Double/Multiple-Flap Only Method 2021
- Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results 2021
- Effect of modified levonorgestrel‐releasing intrauterine system in human adenomyosis with heavy menstrual bleeding 2021
- An Overview of the Basic Knowledge of Levonorgestrel-Releasing Intrauterine System 2021
- Characterization of patients that can continue conservative treatment for adenomyosis 2021
- Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment 2021
- Laparoscopic adenomyomectomy combined with l<scp>evonorgestrel‐releasing</scp> intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness 2020
- Treatment of symptomatic adenomyosis with the levonorgestrel‐releasing intrauterine system 2019
- A study of efficacy of ormeloxifene in treatment of adenomyosis 2019
- [Progress on medical treatment in the management of adenomyosis]. 2019
- [The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis]. 2019
- [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis]. 2019
- Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis 2019
- High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up 2019
- Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study 2018
- LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN ADENOMYOSIS; PREDICTORS FOR RESPONSE AND CLINICAL OUTCOME 2018
- THE CLINICAL EFFICACY OF SEQUENTIAL USE OF GONADOTROPIN-RELEASING HORMONE ANALOG - LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN MEDICALLY ILL WOMEN WITH SYMPTOMATIC AND RELATIVELY LARGE ADENOMYOSIS 2018
- Minimally invasive treatment of adenomyosis 2018
- The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility 2018
- Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma 2018
- Gonadotrophin‐releasing hormone agonist combined with high‐intensity focused ultrasound ablation for adenomyosis: a clinical study 2017
- Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study 2017
- Adenomiosis: tratamiento 2015
- Efficacy of laparoscopic adenomyomectomy using double-flap method for diffuse uterine adenomyosis 2015
- 10.1016/s0246-1064(14)65366-4 2000
Source provenance
- europepmc
- last seen: 2026-06-22T06:15:23.361955+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:18:59.468224+00:00
License: CC0
· commercial use OK